Roles of the Pathologist in Evaluating Surrogate Markers for Medical Therapy in Adrenocortical Carcinoma

Endocrine Pathology

Volumn 25, Issue 4, 2014, Pages 366-370

  Sasano, Hironobu ^a   Satoh, Fumitoshi ^a   Nakamura, Yasuhiro ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adrenal; Carcinoma; Chemotherapy; EGFR; Immunohistochemistry; Mitotane; Pathology; Surrogate marker

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; INITIATION FACTOR 4E BINDING PROTEIN 1; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOTANE; PLATINUM COMPLEX; S6 KINASE; S6K1 PROTEIN; SOMATOMEDIN; STREPTOZOCIN; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; STEROIDOGENIC FACTOR 1;

ADRENAL CORTEX CARCINOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DRUG EFFICACY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; PREDICTION; PROTEIN TARGETING; TREATMENT RESPONSE; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MITOTANE; PATHOLOGY, MOLECULAR; PREDICTIVE VALUE OF TESTS; STEROIDOGENIC FACTOR 1; TUMOR MARKERS, BIOLOGICAL;

EID: 84911807891     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-014-9334-7     Document Type: Article

References (30)

1. Weiss LM. Comparable histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984; 8:163–169,
2. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13:202–206,
3. Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, Proyce C, Wemeau JL, Lecomte-Houcke M, Leteurte E. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 2002; 26:1612–1219
4. Papotti M, Libè R, Duregon E, Volante M, Bertherat J, Tissier F. The Weiss score and beyond–histopathology for adrenocortical carcinoma.Horm Cancer 2011; 2:333–340
5. Duregon E, Fassina A, Volante M, Nesi G, Santi R, Gatti G, Cappellesso R, Dalino Ciaramella P, Ventura L, Gambacorta M, Dei Tos AP, Loli P, Mannelli M, Mantero F, Berruti A, Terzolo M, Papotti M. The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases. Am J Surg Pathol. 2013; 237:1433–1440
6. Sasano H. New approaches in human adrenocortical pathology: assessment of adrenocortical function in surgical specimen of human adrenal glands. Endocr Pathol 1992; 3:4–13
7. Sasano H. Shizawa S. Suzuki T. Takayama K. Fukaya T. Morohashi K. Nagura H. Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy. Human Pathology. 1995; 26:1154–1156
8. Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, Beuschlein F, Willenberg HS, Hahner S, Saeger W, Bertherat J, Allolio B, Fassnacht M. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. Journal of Clinical Endocrinol Metab 2009; 95:161–171
9. Mondal SK, Dasgupta S, Jain P, Mandal PK, Sinha SK. Histopathological study of adrenocortical carcinoma with special reference to the Weiss system and TNM staging and the role of immunohistochemistry to differentiate it from renal cell carcinoma. J Cancer Res Ther 2013; 9:436–441
10. Sangoi AR, Fujiwara M, West RB, Montgomery KD, Bonventre JV, Higgins JP, Rouse RV, Gokden N, McKenney JK. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol 2011; 35:678–86
11. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009; 115:243–250
12. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budaus L, Shariat SF, Guazzoni G, Montorsi F, Karakiewicz PI The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 2010; 46:713–719
13. Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol 2011; 7:323–335
14. Fassnacht M, Allolio B What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin Endocrinol 2011; 73:561–565
15. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi P, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A Adjuvant mitotane treatment in patients with adrenocortical carcinoma. N Engl J Med 2007; 356:372–380
16. Allolio B, Fassnacht M Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinol Metab 2006; 91:2027–2037
17. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. Journal of Clinical Endocrinol Metab 2013; 98:4551–4564
18. Beuschlein F, Obracay J, Saeger W, Prognostic value of histological markers in localized adrenocortical carcinoma after complete resection. Endocr Rev. 2013; 34: 29–33
19. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013; 24:152–160
20. Ronchi C, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg H, Hahner S, Allolio B, Fassnacht M Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocrine-Related Cancer 2009; 16: 907–908
21. Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A, Chanson P, Schlumberger M, Leboulleux S, Baudin E. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocrine-Related Cancer 2010; 17: 797–807
22. Iino K, Oki Y, Sasano H A case of adrenocortical carcinoma associated with recurrence after laparoscopic surgery. Clinical Endocrinology (Oxf) 2000; 53:243–248
23. Volante M, Terzolo M, Fassnacht M, Rapa I, Germano A, Sbiera S, Daffara F, Sperone P, Scagliotti G, Allolio B, Papotti M, Berruti A. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer. Clin Cancer Res. 2012; 18:3452–3461
24. Nakamura M, Miki Y, Akahira JI, Morimoto R, Satoh F, Ishidoya S, Arai Y, Suzuki T, Hayashi Y, Sasano H. An Analysis of Potential Surrogate Markers of Target-Specific Therapy in Archival Materials of Adrenocortical Carcinoma. Endocr Pathol, 2009; 20:17–23
25. Sasano H. Suzuki T. Shizawa S. Kato K. Nagura H. Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. Modern Pathology, 1994; 7:741–746
26. Adam P, Hahner S, Hartmann M, Heinrich B, Quinkler M, Willenberg HS, Saeger W, Sbiera S, Schmull S, Voelker HU, Ströbel P, Allolio B, Fassnacht M. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Mod Pathol. 2010; 23:1596–1604
27. Zhang J, Wang C, Gao J, Sun J, Zeng X, Wu S, Liang Z. Adrenal cortical neoplasms: a study of clinicopathological features related to epidermal growth factor receptor gene status. Diagnostic Pathology 2014; 9:19–26
28. Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH, Lerario AM, Maciel CC, Mattos GE, Jorge AA, Mendonca BB, Latronico AC. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metab. 2008; 93:3524–3531
29. Fraenkel M, Gueorguiev M, Barak D, Salmon A, Grossman AB, Gross DJ. Everolimus therapy for progressive adrenocortical cancer. Endocrine. 2013; 44:187–192
30. De Martino MC, Feelders RA, de Herder WW, van Koetsveld PM, Dogan F, Janssen JA, Waaijers AM, Pivonello C, Lamberts SW, Colao A, de Krijger RR, Pivonello R, Hofland LJ. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. Endocr Relat Cancer 2014; 21:601–613